|
|
|
| Safety and immunogenicity of a split-virion quadrivalent influenza vaccine |
| LIU Shuzhen*, MENG Li, XI Peipei, ZHANG Yongchao, FAN Bei, LI Changgui, XIA Shengli, PAN Ruowen
|
| *National Institutes for Food and Drug Control, Beijing 102629, China |
|
|
|
|
Abstract Objective To evaluate the safety and immunogenicity of a split-virion quadrivalent influenza vaccine.Methods The healthy people aged three years or over in Wuyang County and Xiping County of Henan Province were divided into the experimental group, control group 1 and control group 2, and were vaccinated with split-virion quadrivalent influenza vaccines, split-virion trivalent influenza vaccines (without B/Victoria) and a split-virion trivalent influenza vaccines (without B/Yamagata) , respectively. The hemagglutination inhibition (HI) antibodies were detected before and after immunization. The incidence rate of adverse events following immunization (AEFI) , HI antibody positive conversion rate, the protection rate of HI antibodies and the growth of geometric mean titer (GMT) were calculated and compared with the standard of Food and Drug Administration (FDA).Results Totally 2 924 people were recruited, with 975 in the experimental group, 974 in the control group 1 and 975 in control group 2. The incidence rate of AEFI in the experimental group was 11.7%, higher than 7.9% in control group 1 and 8.8% in control group 2 (P < 0.05) during 30 minutes and 8 days after inoculation. The positive conversion rates of HI antibodies of H1N1, H3N2, By and Bv in the experimental group were 78.5%, 53.3%, 78.3% and 62.9%, respectively. The rate differences of the positive conversion rates of HI antibodies of By between the experimental group and control group 2, and of Bv between the experimental group and control group 1 were 42.1% (95%CI: 38.0%-46.2%) and 33.2% (95%CI: 28.9%-37.5%) , with both lower limits of 95%CI more than -0.10. The GMT increase of HI antibodies was more than 2.5 times in the three groups. The protective rates of HI antibodies of H1N1, H3N2, By and Bv in the experimental group were 87.7%, 98.7%, 93.6% and 77.2%, respectively. The protective rates of HI antibodies of By in control group 2 and Bv in control group 1 were 71.1% and 51.0%, both lower than those in the experimental group (P < 0.05).Conclusions After the inoculation of the quadrivalent influenza vaccine, the positive conversion rates (>40%) , protection rates (>70%) and GMT increase (>2.5 times) of HI antibodies of H1N1, H3N2, By and Bv all meet the quality standards of FDA. The safety and immunogenicity of the quadrivalent influenza vaccine are not inferior to those of the trivalent influenza vaccine.
|
|
Received: 22 June 2020
Revised: 28 August 2020
Published: 09 November 2020
|
|
|
|
|
|
[1] World Health Organization.Vaccines against influenza WHO position paper - November 2012[J]. Wkly Epidemiol Rec,2012,87(47):461-476.
[2] 冯录召,康敏,陈涛,等. 中国流感疫苗预防接种技术指南(2018—2019)[J]. 中华预防医学杂志,2018,52(11):1413-1425.
[3] CRÉPEY P,DE BOER P T,POSTMA M J,et al. Retrospective public health impact of a quadrivalent influenza vaccine in the United States[J]. Influenza Other Respir Viruses,2015(Suppl.1):39-46.
[4] RUDENKO L,KISELEVA I,KRUTIKOVA E,et al. Rationale for vaccination with trivalent or quadrivalent live attenuated influenza vaccines:protective vaccine efficacy in the ferret model[J/OL]. PLoS One,2018,13(12)[2020-08-28]. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0208028.
[5] XIE H,WAN X F,YE Z,et al. H3N2 mismatch of2014-15 northern hemisphere influenza vaccines and head-to-head comparison between human and ferret antisera derived antigenic maps[J/OL]. Sci Rep,2015[2020-08-28]. https://www.nature.com/articles/srep15279. DOI:10.1038/srep15279.
[6] 吴建华,赵越. 四价流感疫苗预防季节性流感的研究[J]. 中华实验和临床病毒学杂志,2013,27(4):319-321.
[7] 李雪迎. 非劣效性设计样本量估算——计数指标[J]. 中国介入心脏病学杂志,2016,24(6):346.
[8] 中华人民共和国国家食品药品监督管理局. 国家药监局关于发布预防用疫苗临床试验不良事件分级标准指导原则的通告(2019年第102号)[EB/OL]. [2020-08-28]. https://www.nmpa.gov.cn/xxgk/fgwj/gzwj/gzwjyp/200510140 10101369_2.html.
[9] 张群慕,廖晓伟. 流感疫苗的不良反应及其发生机制的研究进展[J]. 华西药学杂志,2016,31(3):321-323.
[10] 王娅宁,张海祥,侯延丽,等. 疫苗严重不良反应及其发生机制研究进展[J]. 中国免疫学杂志,2014,30(2):283-286.
[11] YANG D Y,BRACKEN K.Update on the new 9-valent vaccine for human papillomavirus prevention[J]. Can Fam Physician,2016,62(5):399-402.
[12] 武文娣,李克莉,许涤沙,等. 中国2015—2018年3个流感季节流感疫苗疑似预防接种异常反应监测数据分析[J]. 中华预防医学杂志,2019,53(10):987-992.
[13] TINOCO J C,PAVIA-RUZ N,CRUZ-VALDEZ A,et al.Immunogenicity,reactogenicity,and safety of inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine in healthy adults aged ≥18 years:a phase III,randomized trial[J]. Vaccine,2014,32(13):1480-1487.
[14] 姚伟,苏波,沈吉友,等. 四价流感病毒裂解疫苗安全性及免疫原性研究[J]. 微生物学免疫学进展,2018,46(4):7-12.
[15] 吴虓飞,金鑫,胡宇驰,等. 四价流感病毒裂解疫苗的安全性研究[J]. 国际生物制品学杂志,2014,37(5):209-211.
[16] KAI C,XU K,TANG R,et al.Immunogenicity and safety of an inactivated quadrivalent influenza vaccine:a randomized, double-blind,controlled phase III study in healthy population aged ≥3 years[J]. Vaccine,2020,38(37):5940-5946.
[17] 郭雪,马燕丽,康艳先,等. 流感病毒裂解疫苗接种人体后的安全性和免疫原性研究[J]. 中华微生物学和免疫学杂志,2018,38(5):361-365.
[18] 杨北方,邓鹏,郭雪,等. 国产无硫柳汞三价流感病毒裂解疫苗上市后免疫原性和安全性观察[J]. 中国疫苗和免疫,2019,25(2):180-183,214.
[19] 张佩如,祝小平,周良君,等. 国产流行性感冒病毒裂解疫苗安全性及免疫效果观察[J]. 中华预防医学杂志,2009,43(7):615-618.
[20] LUGOVTSEV V Y,VODEIKO G M,STRUPCZEWSKI C M,et al.Generation of the influenza B viruses with improved growth phenotype by substitution of specific amino acids of hemagglutinin[J]. Virology,2007,365(2):315-323. |
|
|
|
